{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "The randomized phase III POST trial aimed to compare the efficacies of two adjuvant S-1-based doublet chemotherapies"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "The randomized phase III POST trial aimed to compare the efficacies of two adjuvant S-1-based doublet chemotherapies"
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "compare the efficacies of two adjuvant S-1-based doublet chemotherapies: S-1 plus cisplatin (SP) and S-1 plus docetaxel (DS)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to validate the nProfiler1 assay using a distinct cohort from the POST trial."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Disease-free survival (DFS) and overall survival (OS), including 5-year survival rates, were calculated for the enrolled patients."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Of the 153 patients in the POST trial, 118 were included in the post-hoc analysis."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "no significant difference in DFS or OS was observed between the SP and DS groups."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 10,
    "max_score": 25
  },
  "model": "gpt-4o"
}